InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Dr. Sazzad Hossain, PhD, MSc, will assume a position as member of the Scientific Advisory Board ("SAB") and, contemporaneously, announced his retirement as Chief Scientific Officer ("CSO").  Dr. Eric C. Hsu, PhD, Vice President, Pre-Clinical Research & Development, will continue to lead the scientific R&D programs of the Company.

Dr. Hossain stated, "InMed's continued success in developing cannabinoids to treat serious diseases is vital to me.  Unfortunately, given recent personal health concerns, I wish to modify my role to that of a scientific advisor.  I look forward to continuing my involvement with the entire team at InMed."  Dr. Hossain concluded, "I believe the Company is in a very strong position to advance important potential treatments to patients with high unmet medical needs."

Eric A. Adams, the Company's President and Chief Executive Officer, commented, "It goes without saying that Dr. Hossain has been influential in building the Company; we are fortunate to continue to benefit from Dr. Hossain's expertise as a member of our SAB.  Dr. Hsu, in conjunction with our entire scientific team, will continue to execute on the Company's many development programs.  Chief among our scientific executive team are Alexandra Mancini, our long-tenured Senior Vice President, Clinical & Regulatory Affairs, and our recent addition of Mike Woudenberg as Vice President, Chemistry, Manufacturing & Controls."

Mr. Adams continued, "As the scientific founder of InMed, Dr. Hossain has provided InMed with several drug development candidates and the fundamental know-how in selecting, validating and developing cannabinoid-based medicines.  This contribution to the Company will continue to provide a strong scientific foundation for years to come.  We look forward to Dr. Hossain's continued involvement with the Company."